Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an announcement.
Hemogenyx Pharmaceuticals announced the exercise of warrants for 67,371 new ordinary shares, generating £235,799 in subscription monies. The new shares will be admitted to trading on the LSE, increasing the total number of issued shares to 5,361,267, which shareholders should use for determining changes in share capital interests.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 82,481
Technical Sentiment Signal: Buy
Current Market Cap: £33.85M
See more insights into HEMO stock on TipRanks’ Stock Analysis page.